

UPDATED REQUIREMENTS FOR ANNUAL GENERAL MEETING

SA Government new COVID-19 restrictions - Registration process required for AGM attendance

Adelaide, Australia, 18 November 2020: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, provides an update to the details of its Annual General Meeting (**AGM**) to be held at 11:00am (ACDT) on Wednesday 25 November 2020 at Thomson Geer Lawyers, Level 7, 19 Gouger Street, Adelaide, South Australia.

Due to the recent outbreak of COVID-19 cases within South Australia and the resulting changes to social distancing requirements announced by the State Government on Monday 16 November 2020, all Shareholders wishing to attend the AGM in person will be required to pre-register their attendance. Details for registration are provided below.

Shareholders are asked not to attend if they are displaying relevant symptoms, have recently visited a known hot-spot or have come into contact with a known or suspected case.

The Company will continue to monitor for any further changes in social distancing and other restrictions that may impact the conduct of the AGM. If there are any further changes to the arrangements for the AGM, the Company will lodge an announcement with the ASX and on its website.

Details to Register to attend AGM

- Phone: +61 (0) 8 8227 1555
- Registration available: Mon-Fri, 9:00am – 16:30pm
- Final day for registrations: Friday 20 November 2020
- Information required: Shareholder details, including SRN/HIN, for each holder account

A confirmation email with details of your registration will be provided prior to the meeting and must be shown on arrival.

Proxy Voting

Shareholders are reminded that the deadline for lodging their Proxy votes is 11:00am (ACDT) Monday 23 November 2020. ***Under the current circumstances, including the potential for further restrictions, the Company encourages all shareholders to lodge their Proxy votes prior to the deadline.***

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of the culture plate streaking process. The Company's second product, the Automated Plate Assessment System (APAS®) is being commercialised through LBT's 50% owned joint venture company Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH. Beckman Coulter have also been appointed as Marketing Agent in Europe to assist in facilitating sales. The APAS® instrument is based upon LBT's intelligent imaging and machine learning software and remains the only US FDA-cleared artificial intelligence technology for automated imaging, analysis and interpretation of culture plates following incubation.

CONTACTS

LBT Innovations	Investor Enquiries
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: jgranger@hawkesburypartners.com